, a biopharmaceutical organization focused on developing and commercializing proved cancer therapies in fresh orphan medication indications, presented additional preclinical data at the American Association of Tumor Research Developments in Brain Cancer Research Conference on the potential for its lead product candidate VAL-083 to treat patients with temozolomide-resistant glioblastoma multiforme . Dennis Brown, DelMar's Chief and co-Founder Scientific Officer, presented an abstract entitled, Dianhydrogalactitol inhibits the development of glioma stem and non-stem cultures, including temozolomide-resistant cell lines, in vitro and in vivo. The info from the in vitro portion and the first in vivo segments of the study previously reported at the 2015 AACR annual meeting demonstrated that: VAL-083 could be efficacious against both stem and non-stem GBM cell cultures, including those resistant to temozolomide ; VAL-083 preserved anti-tumor activity independent of DNA fix enzyme 0-6-methylguanine DNA methyltransferase resistance mechanism; VAL-083 demonstrated an additive effect when coupled with radiation in all cultures tested, suggesting that VAL-083 might become a radiosensitizer in GBM; and VAL-083 was effective against GBM in significantly extending survival time in intracranial xenograft GBM models in a dosage dependent manner, including in GBM xenografts that are traditionally resistant to TMZ www.slimhole.org .
‘Our observations add to an evergrowing body of proof that breast cancer isn’t one homogeneous disease, but rather a disease with many subtypes and takes a selection of new treatment techniques,’ said Eric Winer, MD, the paper’s senior writer and director of Dana-Farber’s Breast Oncology Center. Winer and his co-workers conducted a retrospective analysis of three large nationwide breast cancer research that collectively spanned twenty years and involved more than 6,600 patients to assess the cumulative benefits associated with modern chemotherapy regimens. These sufferers had been enrolled in three consecutive studies for individuals with node-positive breast cancers conducted by the Cancer and Leukemia Group B, a National Malignancy Institute funded cooperative group.